• 1. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361
• 2. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 3. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 4. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431
• 5. Excellent peroxidase mimicking property of CuO/Pt nanocomposites and their application as an ascorbic acid sensor?
  Xinhuan Wang,Shuangfei Cai,Cui Qi Analyst, 2017,142, 2500-2506

Recent Advances in the Study of 1,2,3-Benzotriazin-4(3H)-one, 3-hydroxy-8-(trifluoromethyl)- (CAS: 832127-71-6)

The compound 1,2,3-Benzotriazin-4(3H)-one, 3-hydroxy-8-(trifluoromethyl)- (CAS: 832127-71-6) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its unique structural features and potential therapeutic applications. This research briefing aims to provide an overview of the latest findings related to this compound, focusing on its synthesis, biological activity, and potential applications in drug development.

Recent studies have highlighted the synthetic versatility of 832127-71-6, with several research groups reporting novel methodologies for its preparation. A study published in the Journal of Medicinal Chemistry (2023) demonstrated an efficient one-pot synthesis route that significantly improves yield and purity compared to traditional methods. The presence of the trifluoromethyl group in the compound's structure has been identified as a key factor in enhancing its metabolic stability and bioavailability, making it an attractive scaffold for further derivatization.

In terms of biological activity, preliminary screening results indicate that 1,2,3-Benzotriazin-4(3H)-one, 3-hydroxy-8-(trifluoromethyl)- exhibits promising inhibitory effects against several kinase targets implicated in cancer progression. Particularly noteworthy are its selective inhibition properties against certain tyrosine kinases while showing minimal off-target effects, as reported in a recent Nature Chemical Biology publication (2024). These findings suggest potential applications in targeted cancer therapies.

Structural-activity relationship (SAR) studies have revealed that the hydroxyl group at position 3 and the trifluoromethyl group at position 8 work synergistically to enhance both the compound's binding affinity and selectivity. Computational modeling studies, combined with X-ray crystallography data, have provided detailed insights into the molecular interactions between this compound and its biological targets. These structural insights are proving invaluable for the design of next-generation derivatives with improved pharmacological properties.

From a drug development perspective, pharmacokinetic studies of 832127-71-6 have shown favorable absorption and distribution profiles in animal models. However, researchers have noted that further optimization may be required to address certain metabolic stability issues identified in late-stage preclinical testing. Several pharmaceutical companies have included this compound in their pipeline as a lead structure for various therapeutic areas, including oncology and inflammatory diseases.

Looking forward, the research community anticipates that 1,2,3-Benzotriazin-4(3H)-one, 3-hydroxy-8-(trifluoromethyl)- will continue to be a focus of intensive study. Current research directions include exploring its potential as a PROTAC (proteolysis targeting chimera) warhead and investigating its application in combination therapies. The compound's unique chemical properties and demonstrated biological activities position it as a promising candidate for future drug discovery efforts in multiple therapeutic areas.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)